CoChat

Zinc as adjunct treatment in infants aged between 7 and 120 days with probable serious bacterial infection: a randomised, double-blind, placebo-controlled trial

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Background Serious bacterial infections are a major cause of death in early infancy in developing countries. Inexpensive and accessible interventions that can add to the effect of standard antibiotic treatment could reduce infant mortality. We measured the effect of zinc as an adjunct to antibiotics in infants with probable serious bacterial infection.Methods In this randomised, double-blind, placebo-controlled trial, we enrolled infants aged 7-120 days with probable serious bacterial infection at three hospitals in New Delhi, India, between July 6, 2005, and Dec 3, 2008. With computer-generated sequences, we randomly assigned infants in permuted blocks of six, stratified by whether patients were underweight or had diarrhoea at enrolment, to receive either 10 mg of zinc or placebo orally every day in addition to standard antibiotic treatment. The primary outcome was treatment failure, which was defined as a need to change antibiotics within 7 days of randomisation, or a need for intensive care, or death at any time within 21 days. Participants and investigators were masked to treatment allocation. All analyses were done by intention-to-treat. This trial is registered with ClinicalTrials.gov, number NCT00347386.Findings 352 infants were randomly assigned to receive zinc and 348 to placebo. 332 given zinc and 323 given placebo could be assessed for treatment failure. Significantly fewer treatment failures occurred in the zinc group (34 [10%]) than in the placebo group (55 [17%]; relative risk reduction 40%, 95% CI 10-60, p=0·0113; absolute risk reduction 6·8%, 1·5-12·0, p=0·0111). Treatment of 15 (95% CI eight to 67) infants with zinc would prevent one treatment failure. Ten infants receiving zinc died compared with 17 given placebo (relative risk 0·57, 0·27-1·23, p=0·15).Interpretation Zinc could be given as adjunct treatment to reduce the risk of treatment failure in infants aged 7-120 days with probable serious bacterial infection.Funding Department of Biotechnology, Government of India; the European Commission; the Meltzer Foundation; and the Research Council of Norway.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(12)60477-2

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 92

Metadata

Authors
Bhatnagar, S., Wadhwa, N., Aneja, S., Lodha, R., Kabra, S. K., Natchu, U. C. M., Sommerfelt, H., Dutta, A. K., Chandra, J., Rath, B., Sharma, M., Sharma, V. K., Kumari, M., & Strand, T. A.
Affiliations
  • Translational Health Science and Technology Institute (IN)
  • Lady Hardinge Medical College (IN)
  • All India Institute of Medical Sciences (IN)
  • Harvard University (US)
  • Norwegian Institute of Public Health (NO)
  • Deen Dayal Upadhyay Hospital (IN)
Corresponding author
Bhatnagar, Shinjini
Venue
The Lancet
Publisher
Elsevier BV
Published
2012-06
Volume
379
Issue
9831
Pages
2072-2078
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2119163321
Cited by
90
References
26
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 9 · 2021: 5 · 2020: 5 · 2019: 1 · 2018: 6 · 2017: 7 · 2016: 6 · 2015: 15 · 2014: 7 · 2013: 13 · 2012: 7
FWCI
12.55
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Department of Biotechnology, Ministry of Science and Technology, Government of India (BT/PR5238/MED/14/610/2004)
  • European Commission (INCO-FP6-003740)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Trace Elements in Health
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal and Maternal Infections
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
Keywords
zinc supplementation, serious bacterial infection, infants, treatment failure, infant mortality, infant underweight, diarrhea, intensive care unit admission
MeSH terms
Administration, Oral, Anti-Bacterial Agents, Bacterial Infections, Body Weight, Diarrhea, Infantile, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Infant, Infant, Newborn, Male, Trace Elements, Zinc, Weight Gain, Treatment Failure

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.